Skip Navigation



Glycobiology Advance Access published online on September 26, 2003

Glycobiology, doi:10.1093/glycob/cwh003
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
14/1/1    most recent
cwh003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ångström, J.
Right arrow Articles by Henry, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ångström, J.
Right arrow Articles by Henry, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Submitted on March 4, 2003
Revised on August 31, 2003
Accepted on September 3, 2003

© 2003 Oxford University Press

ORIGINAL ARTICLES

Default biosynthesis pathway for blood-group related glycolipids in human small intestine as defined by structural identification of linear and branched glycosylceramides in a group O Le(a-b-) nonsecretor

Jonas Ångström 1, Thomas Larsson 2, Gunnar C. Hansson 1, Karl-Anders Karlsson 1, and Stephen Henry 3*

1 Institute of Medical Biochemistry, Göteborg University, Box 440, SE 405 30, Sweden
2 Swegene Proteomics Center, Göteborg University, Sweden
3 Glycoscience Research Centre, Auckland University of Technology, Private Bag 92006, Auckland 1020, New Zealand; Kiwi Ingenuity Limited, PO Box 39373, Howick, New Zealand

* To whom correspondence should be addressed. E-mail: kiwi{at}aut.ac.nz.

Abstract

Glycoconjugates of the gastrointestinal tract are important for microbial interactions. The expression of histo-blood group glycosyltransferases both governs the expression of blood group determinants and in part the structure and size of the glycoconjugates. Using neutral glycolipids isolated from the small intestine of a rare blood group O Le(a-b-) ABH secretor-negative (nonsecretor) individual we were able to map the "default" pathway of the individual lacking ABO, Lewis and secretor glycosyltransferases.

Structures were deduced with combined analysis of mass spectrometry (MALDI-TOF and ESI-MS/MS), and 1H nuclear magnetic resonance spectroscopy (500 and 600 MHz 1H NMR). All structures present at a level >5% were structurally resolved and included two extended structures: Gal{beta}4(Fuc{alpha}3)GlcNAc{beta}3(Gal{beta}4[Fuc{alpha}3]GlcNAc{beta}6)Gal{beta}4GlcNAc{beta}3Gal{beta}4Glc{beta}1Cer and Gal{beta}3GlcNAc{beta}3(Gal{beta}4[Fuc{alpha}3]GlcNAc{beta}6)Gal{beta}3GlcNAc{beta}3Gal{beta}4Glc{beta}1Cer.

The first, a novel component, is based on a type 2 chain and bears the Lex glycotopes on both its branches. The second, a major component, is based on a type 1 chain which bears a 3-linked type 1 precursor (Lec) glycotope and a 6-linked Lex glycotope on its branches. This latter structure is identical to that previously isolated from plasma and characterized by MS and GC-MS but not by NMR. Structural resolution of these structures was supported by reanalysis of the blood group H-active decaosylceramides previously isolated from rat small intestine. Other minor linear monofucosylated penta-, hepta- and difucosylated octaosylceramides, some bearing blood group determinants, were also identified.

The cumulative data was used to define a default biosynthesis pathway where it can be seen that carbohydrate chain extension, in the absence of blood group glycosyltransferases, is controlled and regulated by non-blood group fucosylation and branching with type 2 Gal{beta}4GlcNAc branches.


Glycosyltransferase, ABO, Lewis, Secretor, histo-blood group antigen
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
GlycobiologyHome page
C.-H. Lin, Y.-Y. Fan, Y.-Y. Chen, S.-H. Wang, C.-I Chen, L.-C. Yu, and K.-H. Khoo
Enhanced expression of {beta}3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines
Glycobiology, April 1, 2009; 19(4): 418 - 427.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-Y. Fan, S.-Y. Yu, H. Ito, A. Kameyama, T. Sato, C.-H. Lin, L.-C. Yu, H. Narimatsu, and K.-H. Khoo
Identification of Further Elongation and Branching of Dimeric Type 1 Chain on Lactosylceramides from Colonic Adenocarcinoma by Tandem Mass Spectrometry Sequencing Analyses
J. Biol. Chem., June 13, 2008; 283(24): 16455 - 16468.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Mare and M. Trinchera
Comparative Analysis of Retroviral and Native Promoters Driving Expression of beta1,3-Galactosyltransferase beta3Gal-T5 in Human and Mouse Tissues
J. Biol. Chem., January 5, 2007; 282(1): 49 - 57.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
J. Holgersson and J. Lofling
Glycosyltransferases involved in type 1 chain and Lewis antigen biosynthesis exhibit glycan and core chain specificity
Glycobiology, July 1, 2006; 16(7): 584 - 593.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
S. Geysens, T. Pakula, J. Uusitalo, I. Dewerte, M. Penttila, and R. Contreras
Cloning and Characterization of the Glucosidase II Alpha Subunit Gene of Trichoderma reesei: a Frameshift Mutation Results in the Aberrant Glycosylation Profile of the Hypercellulolytic Strain Rut-C30
Appl. Envir. Microbiol., June 1, 2005; 71(6): 2910 - 2924.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.